March 22, 2022 - Strategic options to be explored following Phase 3 study

November 29, 2021 - 1,000 subjects enrolled in RESUME-1

November 24, 2021 - Presentation at Piper Sandler 33rd Annual Healthcare Conference

July 7, 2021 - Neurana Pharmaceuticals Announces Publication in Pain Management

June 25, 2021 - Presentation of CNS Effects Study at ASIPP

June 7, 2021 - 50% of subjects enrolled in RESUME-1

June 1, 2021 - Georgia Erbez and Liz Cermak to join BOD

May 11, 2021 - Presentation at Pain Therapeutics Conference

December 21, 2020 - First patient enrolled in RESUME-1

December 8, 2020 - Positive top-line results from Phase 1 CNS Effects Study

November 24, 2020 - Presentation at Piper Sandler 32nd Annual Healthcare Conference

November 23, 2020 - Publication in the Journal of Pain Research

September 2, 2020 - Phase 2 STAR Study Encore Poster and Phase 3 Overview

August 4, 2020 - Neurana to present at Solebury Trout Private Company Showcase on August 10th

July 30, 2020 - Neurana to present at LifeSci Partners Summer Symposium on August 5th

June 8, 2020 - First patient has been enrolled in the Phase 1 central nervous effects (CNS) clinical study of tolperisone